Ftse Mib
34.339,32
0,55%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.816,69
-0,37%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Arbutus Biopharma Corporation (ABUS) Arbutus Biopharma Corporation (ABUS) Notizie

ABUS

Arbutus Biopharma (ABUS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABUS
DataOraFonteTitoloSimboloCompagnia
09/05/202414:00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:ABUSArbutus Biopharma Corporation
07/05/202413:30GlobeNewswire Inc.Arbutus to Participate in Two Upcoming Investor ConferencesNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202413:30GlobeNewswire Inc.Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
02/05/202413:25GlobeNewswire Inc.Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024NASDAQ:ABUSArbutus Biopharma Corporation
18/04/202413:30GlobeNewswire Inc.Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
04/04/202414:30GlobeNewswire Inc.Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaNASDAQ:ABUSArbutus Biopharma Corporation
05/03/202422:48Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ABUSArbutus Biopharma Corporation
29/02/202413:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ABUSArbutus Biopharma Corporation
29/02/202413:30GlobeNewswire Inc.Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
15/02/202413:30GlobeNewswire Inc.Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
14/02/202422:38Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ABUSArbutus Biopharma Corporation
06/02/202401:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
08/01/202413:30GlobeNewswire Inc.Arbutus Announces 2024 Corporate Objectives and Provides Financial UpdateNASDAQ:ABUSArbutus Biopharma Corporation
21/11/202314:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ABUSArbutus Biopharma Corporation
08/11/202313:30GlobeNewswire Inc.Arbutus to Present at Jefferies London Healthcare ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202322:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ABUSArbutus Biopharma Corporation
07/11/202313:30GlobeNewswire Inc.Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
07/11/202313:15GlobeNewswire Inc.Arbutus Announces CEO, William Collier, to Retire December 31, 2023NASDAQ:ABUSArbutus Biopharma Corporation
24/10/202313:30GlobeNewswire Inc.Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
18/10/202313:30GlobeNewswire Inc.Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual ConferenceNASDAQ:ABUSArbutus Biopharma Corporation
11/10/202314:05GlobeNewswire Inc.Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023NASDAQ:ABUSArbutus Biopharma Corporation
11/09/202322:15GlobeNewswire Inc.Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway ExtendedNASDAQ:ABUSArbutus Biopharma Corporation
03/08/202322:18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ABUSArbutus Biopharma Corporation
03/08/202313:30GlobeNewswire Inc.Arbutus Reports Second Quarter 2023 Financial Results and Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
20/07/202313:30GlobeNewswire Inc.Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate UpdateNASDAQ:ABUSArbutus Biopharma Corporation
13/07/202322:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ABUSArbutus Biopharma Corporation
12/07/202313:30GlobeNewswire Inc.Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of DirectorsNASDAQ:ABUSArbutus Biopharma Corporation
10/07/202322:01GlobeNewswire Inc.Arbutus Appoints Two New ExecutivesNASDAQ:ABUSArbutus Biopharma Corporation
21/06/202313:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ABUSArbutus Biopharma Corporation
21/06/202313:30GlobeNewswire Inc.Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal AntibodyNASDAQ:ABUSArbutus Biopharma Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ABUS

La tua Cronologia

BIT
BPE
Bper Banca
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
NEXI
Nexi S.p.A
BIT
BAMI
Banco BPM
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
PRY
Prysmian
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
FBK
Finecobank
BIT
TIT
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network